Hot-Melt Extrusion as a Platform for Next-Generation Pharmaceutical Manufacturing

Hot-melt extrusion (HME) has evolved from an industrial plastics process into a versatile and efficient technology for pharmaceutical solid dosage form development. Initially used in the 1930s, HME is now widely adopted for producing tablets, capsules, films, implants, and transdermal systems. The technique involves the application of heat and pressure to blend active pharmaceutical ingredients (APIs) with polymers and excipients, resulting in solid dispersions, solutions, or controlled-release matrices. As a solvent-free and continuous manufacturing method, HME aligns with the FDA’s Process Analytical Technology (PAT) framework, enabling real-time monitoring and consistent product quality. Advances in screw designs, particularly twin-screw extruders, have enhanced mixing, temperature control, and scalability, allowing better processing of heat-sensitive drugs compared to single-screw systems. The choice of carriers ranging from hydrophilic and hydrophobic polymers to waxes and plasticizers critically influences drug solubility, stability, and release profiles. Pharmaceutical applications of HME include bioavailability enhancement of poorly soluble APIs, taste masking, sustained- and targeted-release formulations, microencapsulation, and implant development. Furthermore, its adaptability has facilitated innovations in nanotechnology-based drug delivery and continuous wet granulation. Despite challenges such as the thermal sensitivity of certain APIs and limited availability of suitable polymers, HME offers significant advantages, including reduced processing steps, improved uniformity, and scalability for modern drug product manufacturing. Ongoing research highlights its expanding role in personalized medicine and continuous pharmaceutical production, underscoring its potential as a transformative platform in formulation science.